دورية أكاديمية
Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer
| العنوان: | Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer |
|---|---|
| المؤلفون: | Schettini F., Giuliano M., Lambertini M., Bartsch R., Pinato D. J., Onesti C. E., Harbeck N., Luftner D., Rottey S., van Dam P. A., Zaman K., Mustacchi G., Gligorov J., Awada A., Campone M., Wildiers H., Gennari A., Tjan-heijnen V. C. G., Cortes J., Locci M., Paris I., Mastro L. D., De Placido S., Martin M., Jerusalem G., Venturini S., Curigliano G., Generali D. |
| المساهمون: | F. Schettini, M. Giuliano, M. Lambertini, R. Bartsch, D.J. Pinato, C.E. Onesti, N. Harbeck, D. Luftner, S. Rottey, P.A. van Dam, K. Zaman, G. Mustacchi, J. Gligorov, A. Awada, M. Campone, H. Wildier, A. Gennari, V.C.G. Tjan-heijnen, J. Corte, M. Locci, I. Pari, L.D. Mastro, S. De Placido, M. Martin, G. Jerusalem, S. Venturini, G. Curigliano, D. Generali |
| بيانات النشر: | MDPI |
| سنة النشر: | 2021 |
| المجموعة: | The University of Milan: Archivio Istituzionale della Ricerca (AIR) |
| مصطلحات موضوعية: | Anthracycline, Breast cancer, Hormone receptor, Metastatic, Non‐pegylated liposomal doxorubicin, Triple negative, Settore MED/06 - Oncologia Medica |
| الوصف: | Anthracyclines are among the most active chemotherapies (CT) in breast cancer (BC). However, cardiotoxicity is a risk and peculiar side effect that has been limiting their use in clinical practice, especially after the introduction of taxanes. Non‐pegylated liposomal doxorubicin (NPLD) has been developed to optimize the toxicity profile induced by anthracyclines, while maintaining its unquestionable therapeutic index, thanks to its delivering characteristics that increase its diffusion in tumor tissues and reduce it in normal tissues. This feature allows NPLD to be safely administered beyond the standard doxorubicin maximum cumulative dose of 450–480 mg/m2. Following three pivotal first‐line phase III trials in HER2‐negative metastatic BC (MBC), this drug was finally approved in combination with cyclophosphamide in this specific setting. Given the increasing complexity of the therapeutic scenario of HER2‐negative MBC, we have carefully revised the most updated literature on the topic and dissected the potential role of NPLD in the evolving therapeutic algorithms. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/34503231; info:eu-repo/semantics/altIdentifier/wos/WOS:000694139700001; volume:13; issue:17; firstpage:1; lastpage:17; numberofpages:17; journal:CANCERS; http://hdl.handle.net/2434/910132Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85114083798 |
| DOI: | 10.3390/cancers13174421 |
| الإتاحة: | https://doi.org/10.3390/cancers13174421Test http://hdl.handle.net/2434/910132Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.CB3C85DC |
| قاعدة البيانات: | BASE |
| DOI: | 10.3390/cancers13174421 |
|---|